Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||PTEN loss|
|Therapy||AZD6482 + Rucaparib|
|Indication/Tumor Type||triple-receptor negative breast cancer|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PTEN loss||triple-receptor negative breast cancer||sensitive||AZD6482 + Rucaparib||Preclinical - Cell culture||Actionable||In a preclinical study, the combination of Rubraca (rucaparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).||detail...|
|PubMed Id||Reference Title||Details|
|Co-targeting PTEN-defined TNBC with p110beta-isoform specific inhibitor and PARP inhibitor BMN 673: A predictive context to sensitize PARP inhibitors in TNBC||Full reference...|